In a landmark moment for India's space ambitions, Indian astronaut Shubhanshu Shukla has blasted off to the International Space Station (ISS) as part of the Axiom-4 mission , marking the country's return to human spaceflight after a 41-year hiatus . This historic launch from NASA’s Kennedy Space Center in Florida has not only reignited national pride but also officially kickstarted India’s human spaceflight programme . The mission, operated by Axiom Space , includes a four-member international crew that will spend 14 days in orbit , conducting scientific research, outreach programs, and various commercial activities. This momentous occasion places India among a select group of nations capable of sending humans into space and reflects the growing prowess of the Indian space sector . A New Chapter: Shubhanshu Shukla and India’s Astronautical Comeback The last Indian to go to space was Rakesh Sharma in 1984, aboard the Soviet spacecraft Soyuz T-11. Now, in 2025, Shubhanshu...
Hemophilia A, a hereditary bleeding disorder caused by the deficiency of clotting Factor VIII, has long been a challenge for the medical community. With patients often requiring lifelong injections of clotting factors, treatment remains both costly and inconvenient. However, Indian scientists have recently achieved a groundbreaking milestone by successfully testing a gene therapy technique aimed at curing severe Hemophilia A. This innovative approach promises a one-time treatment that could revolutionize the lives of thousands of patients worldwide. Understanding Hemophilia A Hemophilia A is a genetic disorder characterized by the deficiency or malfunction of Factor VIII, an essential protein involved in blood clotting. Patients with severe hemophilia have less than 1% of the normal clotting factor levels, making them prone to spontaneous and potentially life-threatening bleeding episodes. Global and National Impact India has the second-largest hemophilia patient pool globally, with e...